Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIBR 1048 MS dose 5
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BIBR 1048 MS dose 5 refers to the 400 mg dose level (dose group 5) of dabigatran etexilate mesylate (BIBR 1048 MS) administered as an oral drinking solution in a first-in-human, single ascending dose Phase 1 clinical study. Developed by Boehringer Ingelheim, dabigatran etexilate is an orally active prodrug that is rapidly converted in vivo to dabigatran (BIBR 953 ZW), a potent, nonpeptidic direct thrombin inhibitor. Dabigatran reversibly binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated coagulation and platelet aggregation. This specific dose cohort was evaluated in healthy male subjects to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug for the prevention and treatment of thromboembolic conditions, such as venous thromboembolism and stroke in patients with atrial fibrillation.
- Other names
- dabigatran etexilate 400 mgdabigatran etexilate mesylate 400 mgdabigatran etexilate mesylate dose 5
02
Targets
PLG (Plasminogen)F2 (Thrombin)
Beyond the preview
Go deeper on BIBR 1048 MS dose 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIBR 1048 MS dose 5.